3 results
Approved WMORecruiting
Primary objective: To evaluate the comparative long-term safety of TAK-503 treatment (formerly known as SPD503) in children and adolescentsaged 6 to 17 years diagnosed with ADHD for whom stimulants are not suitable, not tolerated, or shown to…
Approved WMORecruiting
To assess the effect of donanemab versus placebo on clinical progression in participants with early symptomatic AD with demonstrated presence of low-medium tau pathology.
Approved WMORecruiting
Primary Objective: • To evaluate anti-tumor activity of vimseltinib using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent radiological review (IRR)Secondary Objectives:• To assess anti-tumor activity of vimseltinib…